Neurana Pharmaceuticals Completes Patient Enrollment in Phase 3 RESUME-1 StudySAN DIEGO, Calif., November 29, 2021 — Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced it has completed...
Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor – QINLOCK Significantly Reduced the Risk of Disease Progression or Death by 85% and Showed Clinically Meaningful Overall Survival in the...
PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute Advances Next Phase of Versamune® Oncology Pipeline FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology...
Recent Comments